934
934
946
946
949
949
939
939
1284
1284
1383
1383
1337
1337
1337
1337
1384
1384
1417
1417
2019
2010
Research Institution (28.9K)University (6K)Hospital (1.8K)Company (750)Foundation (156)Investor (18)Other (15)
1 - 10 of 28,912
Sort by
Publication
ID30247535Published Date2020-04-01JournalBiostatistics (Oxford, England), 2020-04-01, Volume 21
Surrogate evaluation is a difficult problem that is made more so by the presence of interference. Our proposed procedure can allow for relatively easy evaluation of surrogates for indirect or spill-over clinical effects at the cluster level. Our definition of surrogacy is based on the causal-association paradigm (Joffe and Greene, 2009. Related causal frameworks for surrogate outcomes. Biometrics65, 530-538), under which surrogates are evaluated by the strength of the association between a ca…
Publication
ID32205882Published Date2020-04-01JournalNature immunology, 2020-04-01, Volume 21
Although mouse infection models have been extensively used to study the host response to Mycobacterium tuberculosis, their validity in revealing determinants of human tuberculosis (TB) resistance and disease progression has been heavily debated. Here, we show that the modular transcriptional signature in the blood of susceptible mice infected with a clinical isolate of M. tuberculosis resembles that of active human TB disease, with dominance of a type I interferon response and neutrophil acti…
Publication
ID31833428Published Date2020-04-01JournalLeukemia & lymphoma, 2020-04-01, Volume 61
Epstein-Barr virus (EBV) normally infects B cells, but in some persons the virus infects T or NK cells. Infection of B cells can result in infectious mononucleosis, and the virus is associated with several B cell malignancies including Hodgkin lymphoma, Burkitt lymphoma, and diffuse large B cell lymphoma. Infection of T or NK cells with EBV is associated with extranodal NK/T cell lymphoma, aggressive NK-cell leukemia, systemic EBV-associated T-cell lymphoma, and chronic active EBV disease, wh…
Publication
ID31923087Published Date2020-04-01JournalJournal of acquired immune deficiency syndromes (1999), 2020-04-01, Volume 83
This study aims to evaluate the pharmacokinetics of an increased dose of darunavir (800 mg twice daily) with 100 mg ritonavir during pregnancy and postpartum.Darunavir (DRV) and ritonavir (RTV; r) intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy (DRV/r 800/100 mg bid) and 2-3 weeks postpartum (DRV/r 600/100 mg twice daily). Plasma concentrations of darunavir and ritonavir were measured using high-performance liquid chroma…
Publication
ID31934890Published Date2020-04-01JournalCurrent opinion in allergy and clinical immunology, 2020-04-01, Volume 20
To present and discuss key design concepts for optimizing the impact of observational studies in the field of allergy and to highlight recent findings from NIAID-funded research networks.We discuss three concepts. First, the benefit of prospective, longitudinal observational studies exemplified by recent findings on the seasonal nature of all rhinitis phenotypes in children with asthma and the protective effects of high house dust allergen content during the first year of life on the developm…
Publication
ID31855881Published Date2020-04-01JournalJournal of acquired immune deficiency syndromes (1999), 2020-04-01, Volume 83
VRC01 is a human IgG1 broadly neutralizing antibody (bnAb) that binds to the HIV-1 envelope glycoprotein. It is being evaluated in two ongoing Phase 2b trials, the first efficacy assessment of a passively-administered bnAb for HIV-1 prevention. HVTN 104 was a phase 1 trial of VRC01.We measured serum concentrations and serum neutralization of VRC01 in 1079 longitudinal samples collected after passive administration of VRC01 in 84 HVTN 104 participants. As assays for measuring VRC01 serum neutr…
Publication
ID31913161Published Date2020-04-01JournalAIDS (London, England), 2020-04-01, Volume 34
The contribution of HLA-DR+ memory CD4 T cells to the HIV reservoir during prolonged antiretroviral therapy is unclear as these cells are commonly excluded when assessing for replication-competent HIV. To address this issue, we examined the distribution of genetically intact HIV DNA within HLA-DR- and HLA-DR+ memory CD4 T cells and the RNA transcriptional profile of these cells during antiretroviral therapy.Full-length DNA sequencing was used to examine the HIV DNA landscape within HLA-DR+ an…
Clinical Trial
Clinical Trial IDNCT04151602Start Date2020-04-01Completion Date2024-04-01Study TypeObservationalStatusNot yet recruiting
Tuberculosis (TB) is the leading infectious disease killer globally and leading cause of death in persons with HIV. The most effective way to reduce TB incidence and mortality is to interrupt transmission. This requires finding and treating individuals with TB disease early, including those with subclinical disease. Molecular epidemiologic studies and mathematical models have shown that the primary approach to case finding—household contact tracing—identifies only 8-19% of transmissions in hi…
Publication
ID32085976Published Date2020-04-01JournalMolecular immunology, 2020-04-01, Volume 120
CD8 T cells are among the most vigorous soldiers of the immune system that fight viral infections and cancer. CD8 T cell development, maintenance, activation and differentiation are under the tight control of multiple transcriptional and post-transcriptional networks. Over the last two decades it has become clear that non-coding RNAs (ncRNAs), which consist of microRNAs (miRNAs) and long ncRNAs (lncRNAs), have emerged as global biological regulators. While our understanding of the function of…
Publication
ID32206773Published Date2020-03-24JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020-03-24
In Mali, ivermectin-based onchocerciasis elimination from the Bakoye and Falémé foci, reported in 2009-2012, was a beacon leading to policy shifting from morbidity control to elimination of transmission (EOT). These foci are also endemic for lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to evaluate if onchocerciasis EOT and LF elimination as a…
We found 28,912 documents that match your Search
Research Grants: 10,601
Publications: 15,447
Patents: 1
Clinical Trials: 2,863

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in